louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02520726: PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
Official title: A Randomized, Double-blind, Placebo-controlled Pilot Study of Sertraline for the Prevention of PTSD in Burn Victims
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Post-traumatic Stress Disorder
Keywords: Posttraumatic stress disorder
PTSD
Sertraline
Burns
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2015-08-13
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized, double-blind, placebo-controlled study to determine whether administration of sertraline to patients who exhibit acute stress disorder secondary to severe burns can contribute to the prevention of post-traumatic stress disorder (PTSD).


Eligibility criteria: Inclusion Criteria:

* Victim of a traumatic event leading to personal injury
* Patient experienced a feeling of intense fear, hopelessness, or horror during the course of the event or immediately afterward
* Positive screen on the ASDS (for inclusion in the randomization phase); a total ASDS score of ≥ 37 (including a dissociative score of ≥ 9) will be counted as a positive screen.

Exclusion Criteria:

* Age \< 18
* Pregnant women, lactating women, or women not using acceptable form of birth control
* Epilepsy or head trauma resulting in seizures
* Current or historical schizophrenia, bipolar disorder, mental retardation, OCD, eating disorders, dementia, delirium, or self-injurious behavior
* Current/previously diagnosed PTSD
* History of hypersensitivity to sertraline
* Trauma occurring \> 7 days prior to likely first treatment in the randomization phase of the trial.
* Unable to provide informed consent for participation in the study protocol.
* Patient at high risk of recurrent bleeding despite surgical stabilization
* Patient with a history of serotonin syndrome
* Patient non-fluent in English
* Patient currently prescribed an antidepressant (any SSRI, SNRI, TCA, MAOI, mirtazapine, or trazodone in excess of 100mg per day)

Primary outcomes:
measure: Clinician-Administered PTSD Scale
timeFrame: Month
Secondary outcomes:
measure: Beck Scale for Suicide Ideation
timeFrame: 1 month
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah Hospital
state: Utah
Study officials:
affiliation: University of Utah
name: Brent M Kious, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05081726: fMRI Feasibility Older Hip Fracture Surgery
Official title: Functional MRI in Older People Following Hip Fracture Surgery: a Feasibility Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Magnetic Resonance Imaging
Hip Fractures
Postoperative Delirium
Keywords: older people
postoperative delirium
Functional MRI
Lead sponsor: University of Nottingham
Sponsor class: OTHER
First posted: 2021-10-18
Enrollment: 10
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Older people recovering from hip fracture surgery

Brief summary: An assessment of the feasibility of structural and functional magnetic resonance imaging (MRI) brain scans in older people who have recovered from and older people who never had delirium after hip fracture surgery

Detailed description: Postoperative delirium, an acute sate of confusion occurs with higher frequency in older people. Hip fracture surgery is a procedure associated with an increased risk of postoperative delirium.

In the study the feasibility of achieving structure and functional connectivity imaging of the brain, using magnetic resonance imaging, in older people who are recovering from hip fracture surgery will be assessed.

People who have recovered from post operative delirium and people who did not have postoperative delirium will be included.

Eligibility criteria: Inclusion Criteria:Age

* Age ≥ 65 years
* Cognitively intact
* primary admission for hip fracture surgery

Exclusion Criteria:

* Cognitive impairment
* Less than moderate level of activities of daily living
* History of neurosurgery/significant head trauma
* Acutely unwell/moribund
* Presence of neurological diseases including overt stroke, dementia, multiple sclerosis, Parkinson's disease, intracranial tumours and other significant neurologic disorders.
* Postural or movement disorders likely to impede MRI scan
* Contraindications to MRI
* Complex fractures/multiple injuries

Primary outcomes:
measure: Feasibility of MRI in older people following hip fracture surgery assessed by tolerability of transfer to scanner and the scanning process
timeFrame: From time of consent to day after MRI scan which is up to 5 days
Secondary outcomes:
measure: Abnormalities of functional connectivity
timeFrame: Up to one month after scans have been achieved
measure: Pain assessment.
timeFrame: From immediately prior to transfer to the MRI suite until return to own hospital bed which is approximately 2 hours
measure: Actual times taken to achieve scans
timeFrame: Up to 60 minutes
measure: Participant feedback
timeFrame: Two occassions. The first immediately after return from the MRI scan suite. The second will occur the day after scanning. Each will take 5 minutes.
Other outcomes:
Locations:
Study officials:
affiliation: University of Nottingham
name: Rob Dineen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03871426: Manual Therapy Effects on Upper and Lower Esophageal Sphincter Pressures
Official title: Manual Cervical Traction and Trunk Stabilization Causes Significant Changes in Lower and Upper Esophageal Sphincter
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastroesophageal Reflux Disease
Globus Pharyngeus
Keywords: High resolution manometry
globus pharyngeus
gastroesophageal reflux disease
manual cervical traction
trunk stabilization maneuver
Lead sponsor: University Hospital, Motol
Sponsor class: OTHER
First posted: 2019-03-12
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Gastroesophageal reflux disease

Brief summary: The aim of this study is to test the influence of manual cervical traction and chest stabilization maneuvers on pressures in upper and lower esophageal sphincters.

Detailed description: High Resolution Manometry (HRM) will be used to measure pressure changes in upper esophageal sphincter (UES) and lower esophageal sphincter (LES) during manual cervical traction and trunk stabilization maneuvers. 50-55 gastroesophageal reflux disease (GERD) subjects will participate in the study. UES and pressures will first be measured in relaxed supine position then, during manual cervical traction and finally, the subjects will undergo manual positioning of the trunk into neutral position and LES and UES pressures will be measured again.

Eligibility criteria: Inclusion Criteria:

* Gastroesophageal reflux disease

Exclusion Criteria:

* Previous gastro- esophageal surgery
* Concomitant other chronic disease that would affect esophageal motility
* Esophageal structural pathology
* Massive hiatus hernia

Primary outcomes:
measure: Pressure in upper and lower esophageal sphincter
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Prague
country: Czechia
facility: Department of Rehabilitation and Sports Medicine, University Hospital Motol, Prague, Czech Republic
Study officials:
affiliation: Department of Rehabilitation and Sports Medicine, University Hospital Motol, Prague, Czech Republic
name: Alena Kobesova, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bitnar P, Stovicek J, Andel R, Arlt J, Arltova M, Smejkal M, Kolar P, Kobesova A. Leg raise increases pressure in lower and upper esophageal sphincter among patients with gastroesophageal reflux disease. J Bodyw Mov Ther. 2016 Jul;20(3):518-24. doi: 10.1016/j.jbmt.2015.12.002. Epub 2015 Dec 17.
Clinical trial NCT00379626: Cognitive and Hormonal Treatment of Sex Offenders
Official title: Cognitive Group and Hormonal Treatment of Sex Offenders.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Paraphilia
Keywords: Paraphilia
Hormonal treatment
Cognitive treatment
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2006-09-22
Enrollment: 5
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine if Cognitive treatment and hormone treatment can change the relapse rate of sexual offenders.

Detailed description: The aim of this study is to determine if Cognitive treatment and hormone treatment can change the relapse rate of sexual offenders.

In the first part of study we are studying changes in the offenders cognitive distortions and in the second part we are studying changes in sexual activities and sexual thoughts after treatment with Leuprorelin. The study is an open pre and post study.

Eligibility criteria: Inclusion Criteria:

Men sentenced for paraphilia

Exclusion Criteria:

Men above 70 years and men that does not speak english

Primary outcomes:
measure: The degree of cognitive distortions after treatment
timeFrame: 8 months
Secondary outcomes:
measure: Locus of control after treatment in part one.
timeFrame: 8 months
measure: Degree of mental health problems (SCL-90)
timeFrame: 8 months
measure: The testosterone levels before, during and after treatment
timeFrame: baseline upto 8 months
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs Hospital. Departement for forensic psyciatry, Brøset.
Study officials:
affiliation: St. Olavs Hospital, Departement of forensic psychiatry, Brøset
name: Jim Aa Nøttestad, Dr. Philos
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nottestad JA, Bjarnar E, Lundmo PI, Sandvik M. [Treatment of sex offenders with leuprorelin]. Tidsskr Nor Laegeforen. 2006 Feb 23;126(5):633-4. No abstract available. Norwegian.
Clinical trial NCT01186926: Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea
Official title: Australian Prospective Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Obstructive Sleep Apnea
Keywords: Obstructive sleep apnea
OSA
hypoglossal nerve stimulation
sleep apnea
Lead sponsor: Apnex Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2010-08-23
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The overall goal of the study is to evaluate the safety, efficacy and therapy settings of the HGNS System for stimulating the hypoglossal nerve to help maintain an open airway in subjects with obstructive sleep apnea (OSA).


Eligibility criteria: Eligibility Criteria

1. Previously diagnosed with moderate to severe obstructive sleep apnea.
2. Subject has failed or does not tolerate CPAP treatment.
3. Age between 21 and 70 years.
4. Body mass index (BMI) less than or equal to 40

Primary outcomes:
measure: Mean change in AHI measured with in-lab nighttime polysomnography (PSG) compared to baseline
timeFrame: 6 months post-implant
measure: Adverse event profile interoperatively, perioperatively, and long term post implant
timeFrame: 1, 3, 6, 12, 24, and 36 months post implant
Secondary outcomes:
measure: Mean change in functional outcomes measured with the Functional Outcomes of Sleep Questionnaire (FOSQ) compared to baseline
timeFrame: 6 months post-implant
Other outcomes:
Locations:
Study officials:
affiliation: Institute for Breathing and Sleep, Austin Health
name: Maree Barnes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: West Australian Sleep Disorders Research Institute, St. Charles Gardner Hospital
name: David Hillman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Adelaide Institute for Sleep Health, Repatriation General Hospital
name: Doug McEvoy, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Westmead Hospital Dept of Respiratory Medicine
name: John Wheatley, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Eastwood PR, Barnes M, Walsh JH, Maddison KJ, Hee G, Schwartz AR, Smith PL, Malhotra A, McEvoy RD, Wheatley JR, O'Donoghue FJ, Rochford PD, Churchward T, Campbell MC, Palme CE, Robinson S, Goding GS, Eckert DJ, Jordan AS, Catcheside PG, Tyler L, Antic NA, Worsnop CJ, Kezirian EJ, Hillman DR. Treating obstructive sleep apnea with hypoglossal nerve stimulation. Sleep. 2011 Nov 1;34(11):1479-86. doi: 10.5665/sleep.1380.
Clinical trial NCT01129726: Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Success Rate and Time in Untrained Medical Personnel
Official title: Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Time and Success Rate in Untrained Medical Personnel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transillumination-guided Fiberoptic Intubation Intubation
Keywords: Transillumination-guided
Fiberoptic Intubation
time
success rate
intubation
Lead sponsor: Second Military Medical University
Sponsor class: OTHER
First posted: 2010-05-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Fiberoptic Intubation is the preferred technique to difficult airway. However, when performed by untrained anesthesiologists, bronchoscopic intubation has a high rate of failure. We want to know if the Transillumination-guided Fiberoptic Intubation technique can improves the success rate and time for tracheal intubation performed by inexperienced anesthesiologists; whether this technique improves the success rate and for normal intubations when performed by inexperienced anesthesiologists as well is unknown. Therefore, the authors compared the success rate and time of Fiberoptic Intubation versus the Transillumination-guided Fiberoptic Intubation performed by anesthesiologists inexperienced in Fiberoptic Intubation.


Eligibility criteria: Inclusion Criteria:

* general anesthesia
* ASA I\~II
* Mallampati Score grade I\~II
* thyromental distance ≥6cm
* mouth-open ≥3cm
* body mass index (BMI) ≤30kg/m2

Exclusion Criteria:

* neck and maxillofacial surgeries
* potential risks for regurgitation and pulmonary aspiration
* in pregnancy

Primary outcomes:
measure: time to intubation
timeFrame: Within 3 month
Secondary outcomes:
measure: success rate and postoperative side effect
timeFrame: 2 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital Affiliated to Second Military Medical University
state: Shanghai
city: Shanghai
country: China
facility: Changhai Hospital affiliated to Second Military Medical University
Study officials:
affiliation: Second Military Medical University
name: XiaoMing Deng, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT00614926: Modafinil for Treatment of Fatigue in ALS Patients
Official title: Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Fatigue
Keywords: Fatigue
low energy
ALS
treatment
Lead sponsor: New York State Psychiatric Institute
Sponsor class: OTHER
First posted: 2008-02-13
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this pilot study is to evaluate whether modafinil is helpful in alleviating fatigue, low energy, drowsiness and difficulty concentrating among patients with amyotrophic lateral sclerosis (ALS), and to evaluate incidence and frequency of adverse events, if any.

Detailed description: ALS is an untreatable, progressive, fatal neurodegenerative disease whose etiology is unknown and whose course is relatively rapid (median survival 3 years after diagnosis). Palliative care, including symptom management, can contribute greatly to improved quality of life. In this context, alleviation of fatigue can help maintain function, extend the duration of time when employment is feasible for those still working, and can enable patients to more fully participate in and enjoy social and recreational activities. Given the prevalence of fatigue in this population, identification of effective treatment is a meaningful goal.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of ALS
* Ages 18-80
* Clinically significant fatigue (4.5+ on Fatigue Severity Scale with duration 3+ months plus impairment in 1+ categories of role function)
* Speaks English
* Able and willing to give informed consent
* Can communicate verbally or with assistive device
* Can swallow capsules
* Forced vital capacity 50+%

Exclusion Criteria:

* Untreated hypothyroidism (TSH \> 4.25 UIU/ML)
* Untreated and uncontrolled hypertension
* Clinically significant anemia (HCT \< 33%)
* Untreated or under-treated major depressive disorder
* Current clinically significant suicidal ideation
* Started antidepressant medication for treatment of depression during past 6 weeks
* Currently taking psychostimulant medication
* History or current psychosis or bipolar disorder
* Fecund women not currently using barrier methods of contraception

Primary outcomes:
measure: Participants Considered "Responders" (Scored 1 or 2) on Clinical Global Impressions Scale
timeFrame: 4 weeks
Secondary outcomes:
measure: Number of "Impaired" Scores on Neuropsychological (Brief) Test Battery
timeFrame: 4 weeks
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute-Columbia University
state: New York
Study officials:
affiliation: professor
name: Judith G Rabkin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02992626: Influence of Dogs on Learning in Children
Official title: Influence of Interacting With Dogs on Learning in Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Learning
Human-animal Interaction
Lead sponsor: Swiss Tropical & Public Health Institute
Sponsor class: OTHER
Collaborators: name: University of Basel
First posted: 2016-12-14
Enrollment: 30
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: In a randomised controlled cross-over study, the influence of interacting with a dog on children's learning performance is investigated.


Eligibility criteria: Inclusion Criteria:

* healthy
* 7 - 14 years old
* willingness to participate

Exclusion Criteria:

* medical or psychiatric diagnosis
* medication
* allergia (dogs)
* phobia (dogs)

Primary outcomes:
measure: VLMT (Verbaler Lern- und Merkfähigkeitstest)
timeFrame: 20 Minutes
Secondary outcomes:
measure: Digit Span (from HAWIK-IV)
timeFrame: 5 Minutes
measure: motoric task (from Kaufman Assessment Battery for Children, dt. Version (K-ABC))
timeFrame: 5 Minutes
measure: Heart rate/heart rate variability
timeFrame: 60 Minutes
Other outcomes:
Locations:
city: Aachen
country: Germany
Study officials:
affiliation: Swiss TPH / University of Basel
name: Karin Hediger, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00004326: Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cushing's Syndrome
Keywords: Cushing's syndrome
endocrine disorders
rare disease
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: University of Michigan
First posted: 1999-10-19
Enrollment: 12
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome.

II. Determine whether reduced hippocampal volume is associated with specific memory dysfunction.

III. Examine the relationships of adrenal androgen to hippocampal volume and memory dysfunction.

IV. Examine the reversibility of hippocampal structural changes and cognitive dysfunction after cortisol levels are normalized.

Detailed description: PROTOCOL OUTLINE: Patients undergo a psychiatric evaluation for mood and cognition during confirmation of diagnosis. Neuropsychologic exams include pencil and paper test and a cognitive assessment.

Endocrine studies include dexamethasone and corticotropin-releasing hormone stimulation tests. The hippocampal complex volume is assessed with coronal magnetic resonance imaging.

There is a follow-up 1 year after the initiation of treatment.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

* Adults and teenagers with untreated, spontaneous active Cushing's syndrome
* Diagnosis verified at the University of Michigan Medical Center, including the following: Excessive cortisol secretion measured by urinary-free cortisol, cortisol secretion rate, and plasma cortisol level
* Lack of normal circadian cortisol secretion and failure to suppress following 2 mg of dexamethasone

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Health Systems
state: Michigan
Study officials:
affiliation: University of Michigan
name: Monica N. Starkman
role: STUDY_CHAIR
References:
Clinical trial NCT01979926: Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis
Official title: Double-blind, A Multicenter, Randomized, Placebo-controlled, Parallel, Phase 2 Study to Comparative Evaluate the Efficacy of N02RS1 600mg/Day, 12,00mg/Day in Korean Patients With Acute and Chronic Bronchitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Exacerbation of Chronic Bronchitis
Lead sponsor: PharmaKing
Sponsor class: INDUSTRY
First posted: 2013-11-08
Enrollment: 102
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of N02RS1 600mg and 1,200mg per day in Patients With acute and acute exacerbation of chronic bronchitis for 7 days.


Eligibility criteria: Inclusion Criteria:

* Patients over 18, under 75 years of age
* Patients Acute and Chronic Bronchitis

Exclusion Criteria:

* Patients who have gotten a glucocorticoids treatment within 4 weeks.
* Patients who need treatments of antibiotic and acute bronchitis infection.
* Patients who have gotten teatments of antibiotic,bronchodilator,painkiller and secretagog within 7 days.
* Bronchial asthma patient.
* Patients who have an indication of bleeding.
* Patients who have a serious heart and renal disease or liver ailment or immunosuppressive response.
* Patients who have history of over 3 phage of Chronic obstructiv lung disease
* Bronchiectasis patients.

Primary outcomes:
measure: Safety
timeFrame: 12weeks
Secondary outcomes:
measure: Efficacy
timeFrame: 12weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul Nat'l University of Boramae Hospital
Study officials:
affiliation: Korea Pharmaceutical Manufacturers Association
name: Wayne B An, Bs
role: STUDY_DIRECTOR
References: